“Reports of adverse events following use of the Janssen COVID-19 vaccine under emergency use authorization suggest an increased risk of immune thrombocytopenia during the 42 days following vaccination,” the FDA said in a letter to Janssen Biotech, J&J’s biotech arm.
Immune thrombocytopenia can cause easy or excessive bruising and bleeding, though the FDA said the chance of developing this disorder after vaccination is very low.
The new warning comes about a month after the CDC recommended Americans receive Pfizer or Modern’s COVID-19 vaccine over Johnson & Johnson’s due to concerns about the rare risk of blood clots following the shot.
Read the full letter here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
